In patients with severe hypertriglyceridemia who are at risk for acute pancreatitis, the drug brought about triglyceride reductions of more than 50% in the phase 2 SHASTA-2 study.
A drug targeting mRNA essential for APO C-III production provided a 50% reduction in triglycerides in BRIDGE-TIMI 73a, the largest ever observed in a controlled trial.